Baseline Patient Characteristics
uterine leiomyosarcoma cancer, melanoma
SOLID TUMORS, MELANOMA, SYNOVIAL SARCOMA
Between March 2017 and January 2021, 21 patients with advanced solid tumors, including 7 colorectal, 3 ovarian, 2 pancreatic, and 1 each with appendix, basal cell, breast, lung, melanoma, neuroendocrine, salivary, synovial sarcoma, and uterine leiomyosarcoma cancer, were treated with ME. The median follow-up duration was 15.3 weeks (range, 2–101.1 weeks). All patients were included in the efficacy and safety analyses.The median age was 57 years (range, 34–81 years), and 14 patients (66.7%) were female. ECOG performance status was 0 for 5 patients, 1 for 12 patients, and 2 for 4 patients (Baseline characteristics by dose levelAbbreviation: SD: standard deviation.